Eligible participants Primary Secondary Outcome Clinical context Main clinical assumptions if implemented outcomes outcomes There is no significant difference in mortality Patients receiving Death within 90 Incidence of acute The trial was undertaken in a Renal failure indicated by use of RRT. between treatment and control groups.More fluid resuscitation in days kidney injury, use of society (starch not licensed until Pruritus not clinically significant (resolves patients in the treatment group however are ICU 35%. Proportion RRT, new organ 2008 in Australia). There is now no use and has other causes). treated with renal replacement therapy, and excluded = 32% failures, duration of of starch in Australian ICUs. there are also more adverse events in the mechanical ventilation Without the trial, starch would have treatment group. Renal injury is more likely and RRT; and become standard practice in Australia. in the control group. specific mortality. Adult ICU admissions = 123,564 N= 29,566 Outcome Difference in N if implemented Health service Economic Impact QALY Economic Total Economic Impact risk between at 65% cost per on health service impact per impact on control and person or day costs if person QALYS if treatment implemented implemented Primary No statistically significant - - - - - - - differences Secondary Included as - - - - - - - intervention cost Change in intervention costs -$38m - - Totals -$38m Columns may not sum due to rounding. Negative values are savings in the calculations. RRT = renal replacement therapy. ICU = intensive care unit. **If the unrestricted commercial funding amount described above is included, total funding to the CHEST trial will amount to approx. $10m, and the Net Profit will be $27m. The overall consolidated Benefit to Cost ratio will be 4.6:1 (if commercial funding from the PROGRESS trial within the ASTN is also included). Health service/ Health Service outcome cost per Explanation and costing assumptions Reference or Outcome person or day
Outcome Eligible participants if implemented Primary outcomes Secondary outcomes Clinical context Main clinical assumptions There is no significant difference in mortality between treatment and control groups.More patients in the treatment group however are treated with renal replacement therapy, and there are also more adverse events in the treatment group. Renal injury is more likely in the control group. Patients receiving fluid resuscitation in ICU 35%. Proportion excluded = 32% Death within 90 days Incidence of acute kidney injury, use of RRT, new organ failures, duration of mechanical ventilation and RRT; and mortality. The trial was undertaken in a society (starch not licensed until 2008 in Australia). There is now no use of starch in Australian ICUs. Without the trial, starch would have become standard practice in Australia. Renal failure indicated by use of RRT. Pruritus not clinically significant (resolves and has other causes). Adult ICU admissions = 123,564 N= 29,566 Outcome Difference in risk between control and treatment N if implemented at 65% Health service cost per person or day Economic Impact on health service costs if implemented QALY impact per person Economic impact on QALYS if implemented Total Economic Impact Primary No statistically significant differences - - - - - - - Secondary Included as intervention cost - - - - - - - Change in intervention costs Totals -$38m - - -$38m Columns may not sum due to rounding. Negative values are savings in the calculations. RRT = renal replacement therapy. ICU = intensive care unit. **If the unrestricted commercial funding amount described above is included, total funding to the CHEST trial will amount to approx. $10m, and the Net Profit will be $27m. The overall consolidated Benefit to Cost ratio will be 4.6:1 (if commercial funding from the PROGRESS trial within the ASTN is also included). Health Service or Outcome Health service/ outcome cost per person or day Explanation and costing assumptions Reference specific
Supplementary-Appendix-B-Economic-evaluation-of-investigator-initiated-clinical-trials-conducted-by-networks.docx